ArticleRespiratory research2026
Robotic-assisted bronchoscopy-guided cryobiopsy for the diagnosis of ground-glass opacity-predominant peripheral pulmonary nodules.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe combination of shape-sensing robotic-assisted bronchoscopy (ssRAB) and cryobiopsy may improve the diagnostic yield of ground-glass opacities (GGOs). However, the literature on this approach is limited. This study aims to assess the diagnostic yield and safety of ssRAB integrated with mobile cone-beam computed tomography (CBCT)-guided cryobiopsy for GGO-predominant peripheral pulmonary nodules (PPNs).
methodsThis is a single-center retrospective study of patients suspected to have malignant GGO-predominant PPNs (consolidation-to-tumor ratio ≤ 0.5) who underwent ssRAB integrated with mobile CBCT-guided cryobiopsy between November 2024 and June 2025 at Shanghai Chest Hospital. Clinicodemographic data, nodule characteristics, procedure details, diagnostic performance, and complications were analyzed. The primary efficacy outcome was the diagnostic yield. The primary safety outcome was procedure-related and device-related complications.
resultsA total of 55 nodules were biopsied in 40 patients. The mean patient age was 59.2 years, and 75.0% were female. The median nodule size was 12.0 mm (interquartile range, 9.9-16.0) in the largest dimension. Thirty-six nodules were pure GGOs and 19 were mixed GGOs, with 94.5% of nodules lacking a bronchus sign. A tunnel to the target lesion was created in 74.5% of the nodules. The per-nodule diagnostic yield was 87.3%. There were no episodes of major bleeding or pneumothorax. Cryobiopsy provided specimens sufficient for assessment of programmed death-ligand 1 (PD-L1) expression in 11 (84.6%) of 13 patients tested and for genetic testing in all 16 patients (100%) in which it was attempted.
conclusionsssRAB integrated with mobile CBCT-guided cryobiopsy had a high diagnostic yield for GGO-predominant PPNs with a favorable safety profile. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.